UNKNOWN EGIA TRI STAPLE
Report
- Report Number
- 1219930-2020-02851
- Event Type
- Injury
- Date Received
- July 17, 2020
- Date of Event
- November 1, 2019
- Report Date
- July 17, 2020
- Manufacturer
- COVIDIEN LP LLC NORTH HAVEN
- Product Code
- GDW
- Adverse Event
- Yes
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- UK
- Reporter Occupation
- OTHER
Narratives
(B)(4). TITLE: ABSTRACTS OF THE ASSOCIATION OF UPPER GASTROINTESTINAL SURGEONS OF GREAT BRITAIN AND IRELAND SOURCE: BJS 2019; 106 (S7): 5¿94 AUGIS ABSTRACTS 2019. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
ACCORDING TO LITERATURE SOURCE OF STUDY PERFORMED BETWEEN OCTOBER 2014 TO MAY 2019, 74 CONSECUTIVE PATIENTS WAS UNDERGOING OESOPHAGECTOMY FOR CANCER BY A SINGLE SURGEON. THE OESOPHAGO-GASTRIC ANASTOMOSIS USED A RELOAD FOLLOWED BY A TWO-LAYERED CLOSURE WITH CONTINUOUS SUTURE, INITIALLY A SUTURE BUT MORE RECENTLY A BARBED SUTURE. THE HYBRID APPROACH (LAPAROSCOPIC GASTRIC MOBILISATION FOLLOWED BY RIGHT THORACOTOMY) WAS INITIALLY UTILIZED IN THE FIRST 47 PATIENTS. SINCE APRIL 2018, ALL PATIENTS UNDERWENT A COMPLETE MINIMALLY INVASIVE OESOPHAGECTOMY (MIO). ADVERSE EVENTS WERE NOTED; ONE PATIENT DEVELOPED A TYPE III CONDUIT NECROSIS REQUIRING OESOPHAGOSTOMY AFTER THE HYBRID APPROACH. FIFTEEN PATIENTS DEVELOPED ANASTOMOTIC STRICTURES REQUIRING A MEDIAN OF ONE DILATATION. FIFTY PERCENT OF PATIENTS WHO HAD ANASTOMOTIC LEAKS DEVELOPED STRICTURES (2/4). THE MEDIAN LENGTH OF STAY WAS 10 DAYS.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 752778 | UNKNOWN EGIA TRI STAPLE | STAPLE, IMPLANTABLE | GDW | COVIDIEN LP LLC NORTH HAVEN | UNKNOWN EGIA TRI STAPLE |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 67 YR | Required Intervention |